Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $11.3 million.

  • Avalo Therapeutics' Non-Current Assets fell 855.61% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.1 million, marking a year-over-year decrease of 753.92%. This contributed to the annual value of $11.8 million for FY2024, which is 600.1% down from last year.
  • Avalo Therapeutics' Non-Current Assets amounted to $11.3 million in Q3 2025, which was down 855.61% from $11.4 million recorded in Q2 2025.
  • Over the past 5 years, Avalo Therapeutics' Non-Current Assets peaked at $18.4 million during Q4 2021, and registered a low of $11.3 million during Q3 2025.
  • Over the past 5 years, Avalo Therapeutics' median Non-Current Assets value was $16.7 million (recorded in 2023), while the average stood at $15.1 million.
  • As far as peak fluctuations go, Avalo Therapeutics' Non-Current Assets surged by 574.53% in 2022, and later tumbled by 2630.43% in 2024.
  • Avalo Therapeutics' Non-Current Assets (Quarter) stood at $18.4 million in 2021, then fell by 7.72% to $17.0 million in 2022, then fell by 25.68% to $12.6 million in 2023, then fell by 6.0% to $11.8 million in 2024, then fell by 4.97% to $11.3 million in 2025.
  • Its last three reported values are $11.3 million in Q3 2025, $11.4 million for Q2 2025, and $11.6 million during Q1 2025.